parent strain m avium atcc 700898 varied (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC parent strain m avium atcc 700898 varied
Parent Strain M Avium Atcc 700898 Varied, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 242 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m+avium/Mycobacterium+avium+Chester/pmc13260134-107-9-13
Average 96 stars, based on 242 article reviews

parent strain m avium atcc 700898 varied - by Bioz Stars, 2026-09

96/100 stars

Images

Chick Chorioallantoic Membrane Assay:

Article Title: Efficacy of carrimycin against Mycobacterium avium complex in vitro and in vivo
Article Snippet: The efficacy of CAM was robust against M. avium (ATCC 25291) and M. intracellulare (ATCC13950) in BALB/c mouse models. .. For M. avium (ATCC 25291), the efficacy of CAM was slightly inferior to AZM. ..

Article Title: Efficacy of carrimycin against Mycobacterium avium complex in vitro and in vivo
Article Snippet: .. The efficacy of CAM was robust against M. avium (ATCC 25291) and M. intracellulare (ATCC13950) in BALB/c mouse models. .. For M. avium (ATCC 25291), the efficacy of CAM was slightly inferior to AZM.

Infection:

Article Title: Efficacy of carrimycin against Mycobacterium avium complex in vitro and in vivo
Article Snippet: .. There is a continuous increase in the bacillary load when mice infected with M. avium (ATCC 25291) show a decrease followed by stabilization when mice infected with M. intracellulare (ATCC 13950). ..

Article Title: Efficacy of carrimycin against Mycobacterium avium complex in vitro and in vivo
Article Snippet: .. They only enhanced the proportion of CD4 + T cells in mice infected with M. intracellulare (ATCC 13950), while showing no impact on mice infected with M. avium (ATCC 25291). ..

other:

Article Title: Berberine and its nanoformulations and extracts: potential strategies and future perspectives against multi-drug resistant bacterial infections
Article Snippet: M. avium , ATCC 25291 , 31.25 , .

Article Title: In vitro assessment of Brazilian red propolis against mycobacteria: antibacterial potency, synergy, inhibition of biofilm formation, and intramacrophage effects
Article Snippet: M. avium (ATCC 25291) , 250 , >1.0 , 0.06.

Activity Assay:

Article Title: Polynuclear Silver(I)–Quinoxaline Complex: Comprehensive Structural Characterization, Antimycobacterial Properties and DNA/BSA Binding Study
Article Snippet: .. Furthermore, the MIC value obtained for the [Ag(NO3)(pqx-2ca)]n complex against M. avium suggests higher activity compared with isoniazid, a standard antitubercular drug [58]. https://doi.org/10.3390/pharmaceutics18020169 * M. tuberculosis H37Ra (ATCC 9431); M. smegmatis (ATCC 607); M. aurum (ATCC 23366); M. avium (ATCC 25291); M. kansasii (ATCC 12478). ..

Clinical Proteomics:

Article Title: Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium
Article Snippet: .. Contezolid , M. abscessus subsp. abscessus (ATCC 19977) M. abscessus subsp. massiliense (CIP108297) Mycobacterium fortuitum (ATCC 6841) Mycobacterium smegmatis (ATCC 19420) Mycobacterium peregrinum (ATCC 700686) M. avium (ATCC 25291) M. intracellulare (ATCC 13950) Mycobacterium kansasii (ATCC 12478) Mycobacterium gordonae (ATCC 14470) Mycobacterium scrofulaceum (ATCC 19981) Mycobacterium marinum (ATCC 927) Mycobacterium xenopi (ATCC 19250) M. abscessus subsp. abscessus (no. of strains = 148) M. abscessus subsp. massiliense (no. of strains = 46) , 16 mg/L 16 mg/L 8 mg/L 1 mg/L 1 mg/L 32 mg/L 64 mg/L 1 mg/L 2 mg/L 1 mg/L 4 mg/L 1 mg/L 0.5–64 mg/L 0.25–64 mg/L , Bacterial protein synthesis inhibitor, interfering with bacterial growth and replication , Phase III clinical trials. .. LCB01-0371 , M. abscessus ATCC 19977 M. abscessus clinical isolates (no. of strains = 8) , 1.2 μg/mL 0.7–22.3 μg/mL , Bacterial protein synthesis inhibitor, interfering with bacterial growth and replication , Phase II clinical trials.

Review